Correction: Endovascular Treatment in Patients with Large Vessel Occlusion Stroke of Different Mechanisms [0.03%]
纠正：不同机制的大血管闭塞卒中的血管内治疗
Zhiyuan Feng,Ming Yang,Aoming Jin et al.
Zhiyuan Feng et al.
Published Erratum
Neurology and therapy. 2025 Jun 5. DOI:10.1007/s40120-025-00776-0 2025
Perampanel as Add-on in Patients Aged ≥ 12 Years with Focal Epilepsy: A Prospective Real-World Observational Study from Southern China [0.03%]
中国南方多中心真实世界研究：帕利哌酮作为年龄≥12岁局灶性癫痫患者的加用药物治疗
Xiaoli Shi,Xiangru Lu,Lixia Li et al.
Xiaoli Shi et al.
Introduction: This study aimed to evaluate the effectiveness, tolerability and safety of perampanel (PER) as an add-on therapy for southern Chinese patients aged ≥ 12 years with focal epilepsy. ...
Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Italy [0.03%]
意大利克拉利din治疗高活跃型复发缓解多发性硬化症的成本效果分析
Barbara Polistena,Anna Maria Provenzano,Caterina Rizzi et al.
Barbara Polistena et al.
Introduction: Multiple sclerosis (MS) is a chronic autoimmune disease impacting the central nervous system. Individuals with highly active relapsing-remitting MS (HA-RRMS) frequently experience symptomatic episodes lastin...
Clinical Spectrum of Acquired Demyelinating Syndromes in Children: A Tertiary Hospital Experience [0.03%]
儿童获得性脱髓鞘综合征的临床谱系：一家三级医院的经验
Mohammed Almuqbil,Lama Aljomah,Nora Almahmoud et al.
Mohammed Almuqbil et al.
Introduction: Although acquired demyelinating syndromes (ADS) are rare in children, the incidence and prevalence of ADS vary internationally. As data on pediatric ADS in Saudi Arabia is limited, the aim of this study was ...
Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry [0.03%]
与其它治疗多发性硬化症的疾病修正疗法相比奥法木单抗的持久性：德国神经病学数据库的结果分析
Stefan Braune,Petra Dirks,Seya Colloud et al.
Stefan Braune et al.
Introduction: Treatment persistence is critical to obtaining full therapeutic benefit and can indicate favorable outcomes. This study examined real-world persistence with ocrelizumab (OCR) versus other disease-modifying t...
Clinical, Humanistic, and Economic Value of 'Good ON-Time' in Advanced Parkinson's Disease: A Multinational Real-World Study [0.03%]
帕金森病晚期“良好按时”治疗的临床、人文和经济效益：一项跨国真实世界研究
Joohi Jimenez-Shahed,Irene A Malaty,Jean-Philippe Azulay et al.
Joohi Jimenez-Shahed et al.
Introduction: In advanced Parkinson's disease (aPD), 'ON-time' indicates periods of better symptom control, with 'good ON-time (GOT)' indicating control without troublesome dyskinesia. Despite its importance, the impact o...
Pharmacokinetics of Atogepant in Healthy Lactating Female Participants: Results from a Phase 1 Lactation Study [0.03%]
健康泌乳女性受试者中阿托加潘的药代动力学：来自一项一期泌乳研究的结果
Ramesh R Boinpally,Jonathan H Smith,Rosa L De Abreu Ferreira et al.
Ramesh R Boinpally et al.
Introduction: Atogepant is approved for the preventive treatment of migraine and is taken orally once daily. This work aimed to characterize the plasma and milk pharmacokinetics of atogepant in lactating females. ...
Managing Aminotransferase Elevations in Patients with Friedreich Ataxia Treated with Omaveloxolone: A Review and Expert Opinion on Use Considerations [0.03%]
酒石酸奥玛乐单抗治疗弗里德赖希共济失调症患者时天冬氨酸转氨酶升高的管理：综述与用药意见专家讨论
Susan Perlman,Mathieu Anheim,Sylvia Boesch et al.
Susan Perlman et al.
Omaveloxolone is approved for the treatment of Friedreich ataxia (FA) in patients aged ≥ 16 years and is under clinical development for pediatric patients. In the MOXIe study, alanine and aspartate aminotransferase (ALT and AST) elevations...
Continuous Dopaminergic Stimulation-Based Levodopa Treatment in Patients with Early to Mid-Stage Parkinson's Disease: A Systematic Review and Meta-Analysis [0.03%]
基于持续多巴胺能刺激的左旋多巴治疗在早中期帕金森病患者中的疗效：系统评价和 meta 分析
Rong Tang,Sunying Zhang,Rui Sun et al.
Rong Tang et al.
Introduction: Despite promising results from continuous dopaminergic stimulation (CDS)-based treatments, the effectiveness of sustained-release formulations of levodopa remains debated. This meta-analysis aims to assess t...
Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies [0.03%]
解读偏头痛机制：一类新型反CGRP单克隆抗体治疗的叙事性回顾研究
Dawn C Buse,Jan Versijpt,Hans-Christoph Diener
Dawn C Buse
This article provides an overview of a symposium held as part of the proceedings at the 10th European Academy of Neurology Congress in Helsinki, Finland, on 2 July 2024. Migraine is a common neurological disease and a leading cause of disab...